Publications by authors named "Ioana-Gabriela Fita"
Article Synopsis
- Tafenoquine, a single 300 mg dose combined with a 3-day chloroquine treatment, is approved for curing Plasmodium vivax malaria in patients 16 and older, offering a more convenient alternative to the traditional multi-day regimens with primaquine.
- * The World Health Organization (WHO) recommends longer primaquine treatments which can lead to poor adherence, whereas tafenoquine's single-dose approach enhances patient compliance.
- * Safety studies indicate that tafenoquine has a similar safety profile to primaquine, but both can cause serious complications in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, so G6PD testing is essential before treatment.*
A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of malaria in patients aged ≥16 years. Recently, however, Watson et al. suggested that the approved dose of tafenoquine is insufficient for radical cure, and that a higher 450 mg dose could reduce P.
View Article and Find Full Text PDFOne of the most common problems encountered in a world characterized by demographic ageing is Alzheimer's disease (AD) with an estimated number of 35.6 million people affected in 2010 to 65.7 million in 2030.
View Article and Find Full Text PDF